Qube Research & Technologies LTD Bellus Health Inc. Transaction History

Qube Research & Technologies LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$7.14 - $8.53 $97,153 - $116,067	13,607 Added 5.45%	263,353 $1.9 Million
Q4 2022 Feb 14, 2023	BUY	$8.22 - $10.76 $613,417 - $802,965	74,625 Added 42.61%	249,746 $2.05 Million
Q3 2022 Nov 14, 2022	BUY	$8.95 - $12.0 $1.57 Million - $2.1 Million	175,121 New	175,121 $1.85 Million
Q3 2021 Nov 12, 2021	SELL	$2.7 - $6.64 $161,643 - $397,523	-59,868 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$3.11 - $4.61 $144,167 - $213,701	46,356 Added 343.07%	59,868 $186,000
Q1 2021 May 14, 2021	BUY	$3.03 - $4.58 $40,941 - $61,884	13,512 New	13,512 $52,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.